Fledgling Recodagen gets first venture round

Seattle's Accelerator has a new fledgling biotech company on its hands. Recodagen is taking flight with an undisclosed amount of money from a Series A venture round. The cash is coming from Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners and WRF Capital. The biotech start-up will work out of an Accelerator facility with technology licensed from Washington State University. It will focus on the genetic mechanism involved in metastasis and the technology developed at Washington State by J. Suzanne Lindsey, who will move to Seattle and become research chief at the company. Recodagen is starting out with three workers.

- read the report from the Seattle Times

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.